Bicycle Therapeutics (NASDAQ:BCYC) Given “Equal Weight” Rating at Stephens

Stephens reissued their equal weight rating on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a research report report published on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock.

Several other brokerages have also recently issued reports on BCYC. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. JMP Securities dropped their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research report on Wednesday, December 18th. B. Riley decreased their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.25.

Bicycle Therapeutics Stock Performance

NASDAQ BCYC opened at $13.20 on Wednesday. The firm has a market cap of $911.46 million, a price-to-earnings ratio of -4.01 and a beta of 0.92. The firm has a 50 day simple moving average of $16.92 and a 200-day simple moving average of $21.34. Bicycle Therapeutics has a one year low of $12.17 and a one year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.26) earnings per share. Equities analysts predict that Bicycle Therapeutics will post -3.05 EPS for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In other news, CTO Michael Skynner sold 3,287 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $46,313.83. Following the transaction, the chief technology officer now directly owns 124,658 shares in the company, valued at approximately $1,756,431.22. This trade represents a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kevin Lee sold 9,038 shares of Bicycle Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $127,345.42. Following the completion of the transaction, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. The trade was a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,933 shares of company stock worth $549,501. Corporate insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Assetmark Inc. acquired a new stake in shares of Bicycle Therapeutics during the third quarter worth about $34,000. GAMMA Investing LLC lifted its position in Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the period. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics during the 4th quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares during the period. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.